Inventor · disambiguated record
Thomas Butler
Also filed as: BUTLER THOMAS · BUTLER THOMAS M
21 granted patents·12 pending applications·613 citations·filing 1988–2025
95Inventor score
Top patents by PatentIndex Score
33 records- 0198US10988498B2Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogsGILEAD SCIENCES INC·Filed 2018·Granted Apr 27, 2021·28 cites·1 claims
- 0298US8853171B21′-substituted carba-nucleoside analogs for antiviral treatmentGILEAD SCIENCES INC·Filed 2012·Granted Oct 7, 2014·75 cites·18 claims
- 0398US8318682B21′substituted carba-nucleoside analogs for antiviral treatmentBUTLER THOMAS·Filed 2011·Granted Nov 27, 2012·110 cites·24 claims
- 0498US8008264B21′-substituted carba-nucleoside analogs for antiviral treatmentGILEAD SCIENCES INC·Filed 2009·Granted Aug 30, 2011·168 cites·24 claims
- 0597USRE46762E1′-substituted carba-nucleoside analogs for antiviral treatmentGILEAD SCIENCES INC·Filed 2016·Granted Mar 27, 2018·28 cites·33 claims
- 0697US8012942B2Carba-nucleoside analogs for antiviral treatmentGILEAD SCIENCES INC·Filed 2010·Granted Sep 6, 2011·107 cites·26 claims
- 0795US10023600B2Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogsBUTLER THOMAS·Filed 2010·Granted Jul 17, 2018·37 cites·2 claims
- 0894US11702421B2Substituted pyridines as irreversible inhibitors of menin-MLL interactionBIOMEA FUSION LLC·Filed 2021·Granted Jul 18, 2023·6 cites·4 claims
- 0993US11084825B2Substituted pyridines as irreversible inhibitors of menin-MLL interactionBIOMEA FUSION LLC·Filed 2019·Granted Aug 10, 2021·19 cites·26 claims
- 1090US11174263B2Inhibitors of menin-MLL interactionBIOMEA FUSION LLC·Filed 2019·Granted Nov 16, 2021·11 cites·25 claims
- 1190US8993116B2Blends of fluoroalkyl-containing ester oligomers with polydicarbodiimide(S)JARIWALA CHETAN P·Filed 2008·Granted Mar 31, 2015·10 cites·17 claims
- 1283US12116371B2Substituted pyridines as irreversible inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Oct 15, 2024·0 cites·14 claims
- 1382US2024376112A1N-[4-[4-(4-MORPHOLINYL)-7H-PYRROLO[2,3-d]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO-2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINE CARBOXAMIDE AND USES THEREOFBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 1480US12077544B2Irreversible inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Sep 3, 2024·0 cites·20 claims
- 1576US12275739B2Inhibitors of menin-MLL interactionBIOMEA FUSION INC·Filed 2023·Granted Apr 15, 2025·0 cites·21 claims
- 1673US2025161320A1Covalent inhibitors of menin-mll interaction for diabetes mellitusBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 1773US2024262795A1Pyrazine compounds as inhibitors of flt3BIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 1871US11945785B2Pyrazine compounds as inhibitors of FLT3BIOMEA FUSION INC·Filed 2022·Granted Apr 2, 2024·0 cites·28 claims
- 1970US2021403497A1Processes and intermediates for the preparation of 1`-substituted carba-nucleoside analogsGILEAD SCIENCES INC·Filed 2021·Application pending·0 cites
- 2069US12251385B2Covalent inhibitors of menin-MLL interaction for diabetes mellitusBIOMEA FUSION INC·Filed 2022·Granted Mar 18, 2025·0 cites·17 claims
- 2169US12018032B2Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interactionBIOMEA FUSION INC·Filed 2022·Granted Jun 25, 2024·0 cites·19 claims
- 2268US11845753B2Inhibitors of menin-mll interactionBIOMEA FUSION INC·Filed 2021·Granted Dec 19, 2023·0 cites·20 claims
- 2362US2025312335A1Flt combination therapy for cancer and compositions thereforBIOMEA FUSION INC·Filed 2023·Application pending·0 cites
- 2462US2025353854A1Fused pyrimidine compounds as inhibitors of meninBIOMEA FUSION INC·Filed 2023·Application pending·0 cites
- 2561US9828722B2Blends of fluoroalkyl-containing ester oligomers with polycarbodiimide(s)3M INNOVATIVE PROPERTIES CO·Filed 2015·Granted Nov 28, 2017·0 cites·18 claims
- 2661US2024343731A1Crystalline forms of an irreversible inhibitor of menin-mll interactionBIOMEA FUSION INC·Filed 2024·Application pending·0 cites
- 2760US2024409558A1Irreversible inhibitors of krasBIOMEA FUSION INC·Filed 2022·Application pending·0 cites
- 2859US2025066386A1Inhibitors of krasBIOMEA FUSION INC·Filed 2022·Application pending·0 cites
- 2959US2025304572A1Heterocyclic glp-1r agonistsBIOMEA FUSION INC·Filed 2025·Application pending·0 cites
- 3058US2025136558A1Pyrazine compounds as irreversible inhibitors of flt3BIOMEA FUSION INC·Filed 2022·Application pending·0 cites
- 3157US2024124467A1Fused pyrimidine compounds as inhibitors of menin-mll interactionBIOMEA FUSION INC·Filed 2021·Application pending·0 cites
- 3256US4948435AMethod for inhibiting stress corrosion crackingBUTLER THOMAS M·Filed 1988·Granted Aug 14, 1990·10 cites·8 claims
- 3332US5018706AApparatus for inhibiting stress corrosion crackingBUTLER THOMAS M·Filed 1990·Granted May 28, 1991·4 cites·6 claims
Join the waitlist — get patent alerts
Get an alert when Thomas Butler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →